Mucositis in patients with hematologic malignancies: an overview

Area of Science:

• Oncology
• Hematology
• Gastroenterology

Background:

• Mucosal barrier injury, or mucositis, is a frequent and severe complication in patients undergoing intensive chemotherapy or myeloablative conditioning for hematopoietic stem cell transplantation.
• This condition significantly increases the risk of infections, necessitates extensive pain management and nutritional support, and prolongs hospitalization.
• Current interventions for mucositis are largely supportive and inadequate for preventing or effectively treating the damage.

Purpose of the Study:

• To review the current understanding of mucositis pathogenesis.
• To explore the development of novel therapeutic strategies for mucositis.
• To highlight the need for targeted approaches to manage this complication.

Main Methods:

• Literature review focusing on mucositis pathogenesis and emerging therapies.
• Analysis of recent advancements in understanding mucosal damage mechanisms.
• Synthesis of data on novel therapeutic options in preclinical and clinical development.

Main Results:

• Recent research has significantly improved the understanding of the molecular and cellular mechanisms underlying mucositis.
• Several novel therapeutic agents targeting specific pathways of mucosal damage are under investigation.
• These new options hold promise for a more targeted and effective approach to mucositis prevention and treatment.

Conclusions:

• Despite advances in supportive care, effective prevention and treatment of mucositis remain critical challenges in hematologic malignancy treatment.
• A deeper understanding of mucositis pathogenesis has paved the way for innovative therapeutic strategies.
• Future research and clinical trials are essential to validate these novel options and improve patient outcomes.